Inclusion Criteria:

• * At least 18 years of age at the time of consent
• * Clinical signs, symptoms, and presentation consistent with acute PE
• * Onset of PE symptoms occurred within 14 days of presentation
• * Filling defect in at least one main or lobar pulmonary artery evidenced by CTA
• * RV dysfunction on CTA or echocardiography defined as RV/LV ratio \>0.9

Exclusion Criteria:

• * tPA use within 14 days prior to baseline CTA
• * Systolic BP \<90 mmHg for 15 min or the requirement of inotropic support to maintain systolic BP ≥90 mmHg
• * Diagnosis of pulmonary hypertension or suspected undiagnosed pulmonary hypertension with peak PA \>70 mmHg by right heart catheterization or elevated main pulmonary artery to aorta ratio (MPA:A)
• * History of severe or chronic pulmonary hypertension
• * FiO2 requirement \>40% or \>6 LPM to keep oxygen saturations \>90%
• * Hematocrit \<28%
• * Platelets \<100,000/µL
• * Serum creatinine \>1.8 mg/dL
• * INR \>3
• * aPTT (or PTT) \>50 seconds on no anticoagulation
• * History of heparin-induced thrombocytopenia (HIT)
• * Recent (within six months) history of stroke, transient ischemic attack (TIA), or intracranial bleeding
• * Recent (within one month) history of active bleeding from a major organ
• * Absolute contraindication to anticoagulation
• * Major trauma such as head trauma, or other active intracranial, or intraspinal disease within 14 days
• * Morbidly obese (BMI \>45 kg/m2) patient who by the judgement of the investigator is high risk for bleeding
• * Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
• * Cardiovascular or pulmonary surgery within last 7 days
• * Cancer which requires active chemotherapy
• * Known serious, uncontrolled sensitivity to radiographic agents
• * Life expectancy \<90 days, as determined by investigator
• * Female who is pregnant
• * Intracardiac thrombus
• * Patients who present with cardiac arrest and/or are on extracorporeal membrane oxygenation (ECMO) or ECMO required to perform interventional procedure
• * Simultaneous participation in another investigational study
• * Patients with known coagulation disorders such as antiphospholipid, Protein C, and Protein S
• * Presentation of PE with paradoxical emboli which may be diagnosed by concurrent stroke or concurrent arterialization